{"Clinical Trial ID": "NCT00089661", "Intervention": ["INTERVENTION 1:", "Denosumab 60 mg Q6M", "[Unspecified]", "INTERVENTION 2:", "- Placebo", "[Unspecified]"], "Eligibility": ["Adenocarcinoma of the breast confirmed histologically or cytologically", "Those with early-stage disease who are positive for estrogen receptors and who have completed their treatment (surgery, chemotherapy, radiotherapy and/or hormone therapy) and are currently in treatment with or are going to be treated with an aromatase inhibitor, and who should remain in treatment with an aromatase inhibitor for the duration of the 24-month study.", "All routes of treatment should be completed 4 weeks prior to entry into the study, and all acute toxic effects of any of the above treatments should be resolved in Class 1 by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Reactions (CTACE)", "Women > 18 years of age", "ECOG Performance status 0 and 1", "\u2022 Lumbar, total hip or femoral neck BMD equivalent to a t-score rating of -1.0 to -2.5", "The subject is willing and able to provide the signed consent prior to any specific procedure under consideration.", "Other criteria also apply."], "Results": ["Performance measures:", "Percentage change in lumbar spine mineral density from baseline at month 12", "\u00b7 Bone mineral density evaluated by double-energy X-ray absorptiometry.", "Time limit: 12 months", "Results 1:", "Title of arm/group: Denosumab 60 mg Q6M", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 123", "Average least squares (95% confidence interval)", "Unit of measure: Percentage change from baseline 4.8 (4.3 to 5.4)", "Results 2:", "Title of the arm/group: Placebo", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 122", "Average least squares (95% confidence interval)", "Unit of measure: Percentage change from baseline -7 (-1,3 to -.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 11/120 (9.17 per cent)", "- Acute myocardial infarction 0/120 (0.00 %)", "Atrial fibrillation 1/120 (0.83%)", "Atrioventricular block second degree 0/120 (0.00 %)", "Congestive heart failure 1/120 (0.83%)", "Myocardial infarction 0/120 (0.00 %)", "Ischaemia myocardial 1/120 (0.83%)", "- Goiter 1/120 (0.83%)", "Ischaemic colitis 0/120 (0.00 %)", "- Diverticulum 0/120 (0.00 %)", "Faecalome 1/120 (0.83%)", "Adverse Events 2:", "Total: 19/129 (14.73 per cent)", "- Acute myocardial infarction 1/129 (0.78%)", "Atrial fibrillation 0/129 (0.00 %)", "Atrioventricular block 1/129 (0.78%)", "- Congestive heart failure 0/129 (0.00 %)", "Myocardial infarction 1/129 (0.78%)", "Myocardial Irchaemia 0/129 (0.00 %)", "0/129 (0.00 per cent)", "Ischemic colitis 1/129 (0.78%)", "Diverticulum 1/129 (0.78%)", "- Fecaloma 0/129 (0.00 %)"]}